EIKN (NASDAQ:EIKN) Now Covered by Analysts at Mizuho

Investment analysts at Mizuho started coverage on shares of EIKN (NASDAQ:EIKN) in a note issued to investors on Monday,Benzinga reports. The firm set an “outperform” rating and a $26.00 price target on the stock. Mizuho’s target price points to a potential upside of 88.68% from the company’s previous close.

Several other research firms also recently weighed in on EIKN. Wall Street Zen upgraded EIKN to a “hold” rating in a research note on Monday, February 16th. Bank of America started coverage on shares of EIKN in a research report on Monday. They set a “buy” rating and a $34.00 target price for the company. Finally, Wedbush assumed coverage on shares of EIKN in a research note on Thursday. They issued an “underperform” rating and a $7.00 target price for the company. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $24.75.

EIKN Stock Performance

EIKN stock opened at $13.78 on Monday. EIKN has a 12 month low of $13.28 and a 12 month high of $17.40.

About EIKN

We are a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing important, innovative medicines to address serious unmet medical needs. We are led by world-renowned drug developers Dr. Roger M. Perlmutter, M.D., Ph.D., and Dr. Roy Baynes, M.D., Ph.D. Our vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Our initial focus is oncology, where we are advancing a pipeline of drug candidates targeting areas of high unmet need in large indications.